Evolent Health, Inc. (NYSE:EVH) Receives Average Rating of “Moderate Buy” from Analysts

Evolent Health, Inc. (NYSE:EVH) has received a consensus recommendation of “Moderate Buy” from the twelve analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $42.70.

A number of equities research analysts recently commented on the stock. Oppenheimer started coverage on shares of Evolent Health in a research report on Friday, March 1st. They set an “outperform” rating and a $45.00 target price for the company. Barclays started coverage on shares of Evolent Health in a report on Wednesday, January 3rd. They issued an “overweight” rating and a $39.00 price target for the company. JPMorgan Chase & Co. decreased their price target on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Friday, March 15th. JMP Securities raised their price target on shares of Evolent Health from $37.00 to $38.00 and gave the stock a “market outperform” rating in a report on Friday, February 23rd. Finally, Canaccord Genuity Group decreased their price target on shares of Evolent Health from $45.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, March 28th.

Evolent Health Trading Down 2.9 %

NYSE:EVH opened at $29.26 on Friday. Evolent Health has a 52 week low of $23.33 and a 52 week high of $36.70. The firm has a 50 day moving average of $31.93 and a 200 day moving average of $30.29. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $3.38 billion, a price-to-earnings ratio of -23.04 and a beta of 1.53.

Evolent Health (NYSE:EVH) last posted its earnings results on Thursday, February 22nd. The technology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.13. Evolent Health had a negative net margin of 5.76% and a positive return on equity of 6.60%. The company had revenue of $556.06 million during the quarter, compared to analysts’ expectations of $541.87 million. As a group, sell-side analysts anticipate that Evolent Health will post 0.87 earnings per share for the current fiscal year.

Institutional Trading of Evolent Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. ICA Group Wealth Management LLC acquired a new stake in shares of Evolent Health in the fourth quarter worth $33,000. Signaturefd LLC grew its position in Evolent Health by 1,470.7% during the fourth quarter. Signaturefd LLC now owns 1,445 shares of the technology company’s stock valued at $48,000 after buying an additional 1,353 shares during the period. NBC Securities Inc. acquired a new stake in Evolent Health during the fourth quarter valued at $69,000. Banque Cantonale Vaudoise acquired a new stake in Evolent Health during the first quarter valued at $88,000. Finally, Nisa Investment Advisors LLC grew its position in Evolent Health by 389.3% during the third quarter. Nisa Investment Advisors LLC now owns 5,035 shares of the technology company’s stock valued at $137,000 after buying an additional 4,006 shares during the period.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.